Evaluation of Serum Preptin Levels in Patients With Polycystic Ovary Syndrome
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-45
SponsorGÜLDEN ANATACA
About this trial
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age and is strongly associated with insulin resistance and metabolic dysfunction. Preptin is a pancreatic peptide co-secreted with insulin and has been implicated in glucose metabolism and insulin resistance. However, limited data exist regarding serum preptin levels in patients with PCOS.
The aim of this study is to evaluate serum preptin levels in women diagnosed with PCOS and to investigate the relationship between preptin levels and insulin resistance parameters.
Eligibility criteria
Qualifiers
Female participants aged 18-45 years
Diagnosis of PCOS according to Rotterdam criteria
BMI <30 kg/m²
No PCOS treatment during the previous 6 months
Disqualifiers
Age <18 years or >45 years
Pregnancy or breastfeeding
PCOS treatment within the previous 6 months
Active infection
Trial design
Treatments tested in this trial
- Not listed
Trial groups
60 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
GÜLDEN ANATACA
Lead sponsor
Istanbul Saglik Bilimleri University
Sponsor institution
Source ClinicalTrials.gov